PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers

By Rui Liu, Youwen Chen, Guangzhi Liu, Chenxi Li, Yurong Song, Zhiwen Cao, Wen Li, Jing-hong Hu, Cheng Lu, Yuanyan Liu. Cell Death and Disease, 2020

782 citations recorded by the source corpus.

Multidrug resistance (MDR) is the dominant challenge in the failure of chemotherapy in cancers. Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that spreads intracellular signal cascades and regulates a variety of cellular processes. PI3Ks are considered significant causes of chemoresistance in cancer therapy. Protein kinase B (AKT) is also a significant downstream effecter of PI3K signaling, and it modulates several pathways, including inhibition of apoptosis, stimulation of cell growth, and modulation of cellular metabolism. This review highlights the aberrant activation of PI3K/AKT as a key link that modulates MDR. We summarize the regulation of numerous major targets correlated with the PI3K/AKT pathway, which is further related to MDR, including the expression of apoptosis-related protein, ABC transport and glycogen synthase kinase-3 beta (GSK-3β), synergism with nuclear factor kappa beta (NF-κB) and mammalian target of rapamycin (mTOR), and the regulation of glycolysis.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/9f100446cfab02f00d36ba545ec463253f9b2ce8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Gautam Sethi
2. D. Fruman

Citations in the corpus

• PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer (2023, background): “PI3K Inhibitors Along the PAM pathway PI3K is a major drug target for cancer treatment since its hyperactivity is remarkably correlated with human tumor progression, enhanced tumor microvessel formation, and increased number of invasive cancer cells [205].”